RxDoctor Payments DataLook up a doctor →

Luis Baez Vallecillo, MD

Hematology & Oncology · San Juan, PRNPI 1265788855

Payments from drug & device makers

$349,866in general payments, 2019–2025

Across 1,117 payments — averaging $313.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$237K
  • Pfizer$30K
  • Lilly USA, LLC$29K
  • E.r. Squibb & Sons, L.L.C.$16K
  • AstraZeneca$11K
  • Eli Lilly Export S.A. Puerto Rico Branch$8K
  • plus $18K from 42 others

What the payments were for

  • Consulting fees$27,18726%
  • Speaking & faculty fees$54,24651%
  • Food & beverage$22,50621%
  • Education$1,3701%
  • Other$1,2801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349,866 in reported general payments places this provider in the 85th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$121,321
Medicare patients
152
Services billed
7,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib225$3,602,269
VerzenioAbemaciclib132$2,053,329
ErleadaApalutamide72$1,099,862
KisqaliRibociclib Succinate50$705,235
TagrissoOsimertinib Mesylate27$447,108
TukysaTucatinib15$391,907
CabometyxCabozantinib S-Malate11$278,619
BosulifBosutinib14$273,916
AlecensaAlectinib Hcl13$236,185
XtandiEnzalutamide11$159,400
LibtayoCemiplimab-Rwlc15$154,803
LonsurfTrifluridine/Tipiracil Hcl12$115,125
FulphilaPegfilgrastim-Jmdb49$103,452
TykerbLapatinib Ditosylate12$65,892
XgevaDenosumab18$58,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Bosulif, Eliquis$30,267$3,890,999262 claims
Lilly USA, LLCVerzenio$29,323$2,053,329132 claims
Johnson & JohnsonErleada, Xarelto$1,973$1,116,94598 claims
NovartisKisqali$4,076$705,23550 claims
AstraZenecaTagrisso$11,498$447,10827 claims
Seagen Inc.Tukysa$272$391,90715 claims
Exelixis Inc.Cabometyx$105$278,61911 claims
Genentech USA, Inc.Alecensa$1,006$236,18513 claims
Astellas Pharma US IncXtandi$225$159,40011 claims
Regeneron Healthcare Solutions, Inc.Libtayo$155$154,80315 claims
Taiho Oncology, Inc.Lonsurf$255$115,12512 claims
AmgenXgeva, Prolia$1,349$86,36134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →